| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Pyxis Oncology, Inc. | Director | Common Stock | 251K | $352K | $1.40 | Mar 26, 2024 | Direct |
| PLIANT THERAPEUTICS, INC. | Director | Common Stock (Right to Buy) | 26.8K | $55.7K | $2.08 | Jun 13, 2024 | Direct |
| IMPEL PHARMACEUTICALS INC | Director | Stock Option (right to buy) | 13.2K | Jun 16, 2023 | Direct | ||
| GW PHARMACEUTICALS PLC | U.S. Chief Commercial Officer | Ordinary Shares | 0 | May 5, 2021 | Direct | ||
| GW PHARMACEUTICALS PLC | U.S. Chief Commercial Officer | Share Options | 0 | May 5, 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| PLRX | PLIANT THERAPEUTICS, INC. | Jun 13, 2024 | 1 | $0 | 4 | Jun 17, 2024 | Director |
| PYXS | Pyxis Oncology, Inc. | Mar 26, 2024 | 1 | $0 | 4 | Mar 28, 2024 | Director |
| IMPL | IMPEL PHARMACEUTICALS INC | Jun 16, 2023 | 1 | $0 | 4 | Jun 20, 2023 | Director |
| PLRX | PLIANT THERAPEUTICS, INC. | Jun 7, 2023 | 1 | $0 | 4 | Jun 8, 2023 | Director |
| IMPL | IMPEL PHARMACEUTICALS INC | Apr 12, 2023 | 1 | $0 | 4 | Apr 14, 2023 | Director |
| IMPL | IMPEL PHARMACEUTICALS INC | Apr 12, 2023 | 0 | $0 | 3 | Apr 13, 2023 | Director |
| PYXS | Pyxis Oncology, Inc. | Mar 24, 2023 | 1 | $0 | 4 | Mar 28, 2023 | Director |
| PLRX | PLIANT THERAPEUTICS, INC. | Mar 6, 2023 | 1 | $0 | 4 | Mar 8, 2023 | Director |
| PLRX | PLIANT THERAPEUTICS, INC. | Mar 6, 2023 | 0 | $0 | 3 | Mar 8, 2023 | Director |
| PYXS | Pyxis Oncology, Inc. | Mar 31, 2022 | 1 | $0 | 4 | Apr 4, 2022 | Director |
| PYXS | Pyxis Oncology, Inc. | Dec 8, 2021 | 1 | $93.9K | 4 | Dec 9, 2021 | Director |
| PYXS | Pyxis Oncology, Inc. | Oct 7, 2021 | 1 | $0 | 4 | Oct 12, 2021 | Director |
| PYXS | Pyxis Oncology, Inc. | Oct 7, 2021 | 0 | $0 | 3 | Oct 7, 2021 | Director |
| GWPH | GW PHARMACEUTICALS PLC | May 5, 2021 | 8 | $0 | 4 | May 7, 2021 | U.S. Chief Commercial Officer |